Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/85788
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE DE ESTADUAL DE CAMPINASpt_BR
dc.typeArtigo de periódicopt_BR
dc.titleQuality Of Life Of Chronic Myeloid Leukemia Patients In Brazil: Ability To Work As A Key Factorpt_BR
dc.contributor.authorHamerschlak N.pt_BR
dc.contributor.authorDe Souza C.pt_BR
dc.contributor.authorCornacchioni A.L.pt_BR
dc.contributor.authorPasquini R.pt_BR
dc.contributor.authorTabak D.pt_BR
dc.contributor.authorSpector N.pt_BR
dc.contributor.authorSteagall M.pt_BR
unicamp.authorDe Souza, C., Universidade Estadual de Campinas (Unicamp), Associação Brasileira de Linfoma e Leucemia, São Paulo, SP, Brazilpt_BR
unicamp.author.externalHamerschlak, N., Hospital Israelita Albert Einstein, Associação Brasileira de Linfoma e Leucemia, Av. Albert Einstein, 627/520, São Paulo, SP, 05651-901, Brazilpt
unicamp.author.externalCornacchioni, A.L., Instituto Da Criança, Hospital de Clínicas Da Universidade de São Paulo (USP), Associação Brasileira de Linfoma e Leucemia, São Paulo, SP, Brazilpt
unicamp.author.externalPasquini, R., Universidade Federal Do Paraná, Associação Brasileira de Linfoma e Leucemia, São Paulo, SP, Brazilpt
unicamp.author.externalTabak, D., CENTRON-Centro de Tratamento Oncológico, Associação Brasileira de Linfoma e Leucemia, São Paulo, SP, Brazilpt
unicamp.author.externalSpector, N., Universidade Federal Do Rio de Janeiro, Associação Brasileira de Linfoma e Leucemia, São Paulo, SP, Brazilpt
unicamp.author.externalSteagall, M., Associação Brasileira de Linfoma e Leucemia, São Paulo, SP, Brazilpt
dc.description.abstractPurpose: The purpose of this study was to evaluate the quality of life (QOL) of patients receiving treatment by the public health system in Brazil for chronic myeloid leukemia (CML), a disease requiring daily and strict compliance to oral medication and regular blood and bone marrow controls, which are invasive exams. Methods: Between 2008 and 2010, patients with CML were surveyed by telephone. Quality of life was evaluated by the functional assessment of chronic illness therapy (FACIT) tool. Results: The mean QOL among CML patients was 92.53 (out of 124 total points) in the trial outcome index, 78.50 (out of 108) in the general total score, and 130.43 (out of 176) in the leukemia total score. Patients who had the prescriptions recently changed anyway had better QOL general score (p=0.012) and leukemia-specific score (p=0.043) than those who remained with the same treatment. Imatinib was not associated with this change in QOL (p>0.797). The more the patient felt able to work, the higher the scores in all three FACIT scales (p<0.001, Spearman's correlation). The use of imatinib (p=0.012) was associated with a better ability to work, while chemotherapy (p=0.017) and the use of hydroxyurea (p=0.001) were inversely associated with work capability. Conclusions: A recent change in medication can improve quality of life. The ability to work is an important component of quality of life of patients with CML. Ability to work should be specifically considered in CML treatment. © 2014 Springer-Verlag.en
dc.relation.ispartofSupportive Care in Cancerpt_BR
dc.publisherSpringer Verlagpt_BR
dc.date.issued2014pt_BR
dc.identifier.citationSupportive Care In Cancer. Springer Verlag, v. 22, n. 8, p. 2113 - 2118, 2014.pt_BR
dc.language.isoenpt_BR
dc.description.volume22pt_BR
dc.description.issuenumber8pt_BR
dc.description.firstpage2113pt_BR
dc.description.lastpage2118pt_BR
dc.rightsfechadopt_BR
dc.sourceScopuspt_BR
dc.identifier.issn9414355pt_BR
dc.identifier.doi10.1007/s00520-014-2196-1pt_BR
dc.identifier.urlhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84905119542&partnerID=40&md5=5a93422bff810c65dc2020419c1c848apt_BR
dc.date.available2015-06-25T17:50:13Z
dc.date.available2015-11-26T15:30:25Z-
dc.date.accessioned2015-06-25T17:50:13Z
dc.date.accessioned2015-11-26T15:30:25Z-
dc.description.provenanceMade available in DSpace on 2015-06-25T17:50:13Z (GMT). No. of bitstreams: 1 2-s2.0-84905119542.pdf: 174881 bytes, checksum: 4d330e8f0b9fe6d3bfbdba0c1514a661 (MD5) Previous issue date: 2014en
dc.description.provenanceMade available in DSpace on 2015-11-26T15:30:25Z (GMT). No. of bitstreams: 2 2-s2.0-84905119542.pdf: 174881 bytes, checksum: 4d330e8f0b9fe6d3bfbdba0c1514a661 (MD5) 2-s2.0-84905119542.pdf.txt: 33364 bytes, checksum: 9573cabf54cbaa84c30779c92140ecba (MD5) Previous issue date: 2014en
dc.identifier.urihttp://www.repositorio.unicamp.br/handle/REPOSIP/85788
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/85788-
dc.identifier.idScopus2-s2.0-84905119542pt_BR
dc.description.referenceSaussele, S., Lauseker, M., Gratwohl, A., Beelen, D.W., Bunjes, D., Schwerdtfeger, R., Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: Evaluation of its impact within a subgroup of the randomized German CML Study IV (2010) Blood, 115 (10), pp. 1880-1885pt_BR
dc.description.referenceLee, S.J., Kukreja, M., Wang, T., Giralt, S.A., Szer, J., Arora, M., Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia (2008) Blood, 112 (8), pp. 3500-3507pt_BR
dc.description.referenceDowling, M., Meenaghan, T., Kelly, M., Treating chronic myeloid leukaemia: NICE guidance (2012) Br J Nurs, 21 (4), pp. S16-S17pt_BR
dc.description.referenceDobbin, J.A., Gadelha, M.I.P., Imatinib Mesylate in the treatment of chronic myelogenous leukemia (2002) Rev Bras Cancerol, 48 (3), pp. 429-438pt_BR
dc.description.referenceHahn, E.A., Glendenning, G.A., Sorensen, M.V., Hudgens, S.A., Druker, B.J., Guilhot, F., Larson, R.A., Cella, D., Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS study (2003) Journal of Clinical Oncology, 21 (11), pp. 2138-2146. , DOI 10.1200/JCO.2003.12.154pt_BR
dc.description.referenceEfficace, F., Cocks, K., Breccia, M., Sprangers, M., Meyers, C.A., Vignetti, M., Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: Inclusion of quality of life and other patient-reported outcomes (2012) Crit Rev Oncol Hematol, 81 (2), pp. 123-135pt_BR
dc.description.referenceHamerschlak, N., Pietrocola, M., Tabak, D., Lerner, D., Chiattone, C., Hungria, V., Treatment of accelerated (AP) and blastic phase (BP) of Philadelphia (Ph) chromosome positive chronic myeloid leukemia (CML) with imatinib (2003) Proc Am Soc Clin Oncol, 22 (ABSTR 2479). , http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview= abst_detail_view&confID=23&abstractID=103947, Available from: Accessed in 2012 (Aug 28)pt_BR
dc.description.referenceCortes, J., De Souza, C., Ayala-Sanchez, M., Bendit, I., Best-Aguilera, C., Enrico, A., Current patient management of chronic myeloid leukemia in Latin America: A study by the Latin American Leukemia Net (LALNET) (2010) Cancer, 116 (21), pp. 4991-5000pt_BR
dc.description.referenceSaglio, G., Kim, D.W., Issaragrisil, S., Le Coutre, P., Etienne, G., Lobo, C., Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia (2010) N Engl J Med, 362 (24), pp. 2251-2259pt_BR
dc.description.referenceKantarjian, H., Shah, N.P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia (2010) N Engl J Med, 362 (24), pp. 2260-2270pt_BR
dc.description.referenceKantarjian, H., Shah, N.P., Hochhaus, A., Cortes, J.E., Shah, S., Ayala, M., Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study (2010) Journal of Clinical Oncology, 28 (18 SUPPL.), pp. LBA6500. , http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/LBA6500, Available from: Accessed in 2012 (Aug 28)pt_BR
dc.description.referenceSaglio, G., Kim, D.W., Issaragrisil, S., Le Coutre, P., Etienne, G., Lobo, C., Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia (2010) N Engl J Med, 362 (24), pp. 2251-2259pt_BR
dc.description.referenceLarson, R.A., Le Coutre, P.D., Reiffers, J., Hughes, T.P., Saglio, G., Edrich, P., Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year (2010) Journal of Clinical Oncology, 28 (15 SUPPL.), p. 6501. , http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/6501, Available from: Accessed in 2012 (Aug 28)pt_BR
dc.description.referenceTerasawa, T., Dahabreh, I., Trikalinos, T.A., BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors inpatients with chronic myeloid leukemia (2010) PLoS Curr, 2, pp. RRN1204. , Version 2pt_BR
dc.description.referencePinilla-Ibarz, J., Cortes, J., Mauro, M.J., Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications (2011) Cancer, 117 (4), pp. 688-697pt_BR
dc.description.referenceJabbour, E., Cortes, J., Kantarjian, H., Long-term outcomes in the second-line treatment of chronic myeloid leukemia: A review of tyrosine kinase inhibitors (2011) Cancer, 117 (5), pp. 897-906pt_BR
dc.description.referenceIacobucci, I., Rosti, G., Amabile, M., Poerio, A., Soverini, S., Cilloni, D., Testoni, N., Martinelli, G., Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment (2006) Journal of Clinical Oncology, 24 (3), pp. 454-459. , DOI 10.1200/JCO.2005.03.2011pt_BR
dc.description.referenceQuintás-Cardama, A., Kantarjian, H., Jones, D., Shan, J., Borthakur, G., Thomas, D., Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy (2009) Blood, 113 (25), pp. 6315-6321pt_BR
dc.description.referencePellegrino, E.D., Is truth telling to the patient a cultural artifact? (1992) JAMA, 268 (13), pp. 1734-1735pt_BR
dc.description.referenceFaria, S.L., Souhami, L., Communication with the cancer patient. Information and truth in Brazil (1997) Annals of the New York Academy of Sciences, 809, pp. 163-171pt_BR
dc.description.referenceGulinelli, A., Aisawa, R.K., Konno, S.N., Morinaga, C.V., Costardi, W.L., Antonio, R.O., Desire of information and participation in therapeutic decisions concerning severe diseases, in patients of a University Hospital (2004) Rev Assoc Med Bras, 50 (1), pp. 41-47pt_BR
dc.description.referenceRigatos, G.A., Cancer and truth-telling in Greece. Historical, statistical, and clinical data (1997) Ann N Y Acad Sci, 809, pp. 383-392pt_BR
dc.description.referenceHall, J.A., Roter, D.L., Katz, N.R., Meta-analysis of correlates of provider behavior in medical encounters (1988) Med Care, 26 (7), pp. 657-675pt_BR
dc.description.referenceDa, S.C.H.M., Guerino, C.R.L., Borges, T.R., Marquez, C.T., Boaventura, D.A.C., Gontijo, D.G., Diniz, S.J., De Paula, R.L., Not telling the truth in the patient-physician relationship (2003) Bioethics, 17 (5-6), pp. 417-424pt_BR
dc.description.referenceSuchman, A.L., Matthews, D.A., What makes the patient-doctor relationship therapeutic? Exploring the connexional dimension of medical care (1988) Annals of Internal Medicine, 108 (1), pp. 125-130pt_BR
dc.description.referenceFarsi, Z., Nayeri, N.D., Negarandeh, R., The coping process in adults with acute leukemia undergoing hematopoietic stem cell transplantation (2012) J Nurs Res, 20 (2), pp. 99-109pt_BR
dc.description.referenceGrant, M., Cooke, L., Williams, A.C., Bhatia, S., Popplewell, L., Uman, G., Forman, S., Functional status and health-related quality of life among allogeneic transplant patients at hospital discharge: A comparison of sociodemographic, disease, and treatment characteristics (2012) Support Care Cancer, 20 (11), pp. 2697-2704pt_BR
dc.description.referenceHolloway, S., Lord, K., Bethelmie-Bryan, B., Shepard, M.W., Neely, J., McLemore, M., Managing chronic myeloid leukemia: A coordinated team care perspective (2012) Clin Lymphoma Myeloma Leuk, 12 (2), pp. 88-93pt_BR
dc.description.referenceYost, K.J., Sorensen, M.V., Hahn, E.A., Glendenning, G.A., Gnanasakthy, A., Cella, D., Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the functional assessment of cancer therapy-biologic response modifiers (FACT-BRM) instrument (2005) Value in Health, 8 (2), pp. 117-127. , DOI 10.1111/j.1524-4733.2005.08202.xpt_BR
dc.description.referenceDeininger, M.W., Chronic myeloid leukemia: An historical perspective (2008) Hematology Am Soc Hematol Educ Program, p. 418pt_BR
dc.description.referenceAziz, Z., Iqbal, J., Aaqib, M., Akram, M., Saeed, A., Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronicmyeloid leukemia (2011) Leuk Lymphoma, 52 (6), pp. 1017-1023pt_BR
dc.description.referenceEfficace, F., Baccarani, M., Breccia, M., Alimena, G., Rosti, G., Cottone, F., Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population (2009) Blood, 118 (17), pp. 4554-4560pt_BR
dc.description.referencePhillips, K.M., Pinilla-Ibarz, J., Sotomayor, E., Lee, M.R., Jim, H.S., Small, B.J., Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A controlled comparison (2013) Support Care Cancer, 21 (4), pp. 1097-1103pt_BR
dc.description.referenceEfficace, F., Baccarani, M., Breccia, M., Cottone, F., Alimena, G., Deliliers, G.L., Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib (2013) Leukemia, 27 (7), pp. 1511-1519pt_BR
dc.description.referenceEfficace, F., Rosti, G., Cottone, F., Breccia, M., Castagnetti, F., Iurlo, A., Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors (2013) Leuk Res, , doi:10.1016/j.leukres.2013.07.003, [Epub ahead of print] PubMed PMID: 23906625pt_BR
dc.description.referenceEfficace, F., Rosti, G., Aaronson, N., Cottone, F., Angelucci, E., Molica, S., Patient versus physician symptom and health status reporting in chronic myeloid leukemia (2013) Haematologica, 92 (1), pp. 22-24. , [Epub ahead of print] PubMed PMID: 24241488pt_BR
dc.description.referenceHirji, I., Gupta, S., Goren, A., Chirovsky, D.R., Moadel, A.B., Olavarria, E., Chronic myeloid leukemia (CML): Association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective (2013) Health Qual Life Outcome, 11, p. 167. , PubMed PMID: 24099272pt_BR
dc.description.referenceEfficace, F., Cardoni, A., Cottone, F., Vignetti, M., Mandelli, F., Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: A systematic review (2013) Leuk Res, 37 (2), pp. 206-213pt_BR
dc.description.referenceHochhaus, A., O'Brien, S.G., Guilhot, F., Druker, B.J., Branford, S., Foroni, L., Six-year follow-up of patients receiving imatinib for the first-line treatment of chronicmyeloid leukemia (2009) Leukemia, 23 (6), pp. 1054-1061pt_BR
dc.description.referenceDe Almeida, M.H., Pagnano, K.B., Vigorito, A.C., Lorand-Metze, I., De Souza, C.A., Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: A Brazilian single-center cohort (2013) Acta Haematol, 130 (1), pp. 16-22pt_BR
dc.description.referenceWebster, K., Cella, D., Yost, K., The functional assessment of chronic illness therapy (FACIT) measurement system: Properties, applications, and interpretation (2003) Health Qual Life Outcomes, 1, p. 79pt_BR
dc.description.referenceBrucker, P.S., Yost, K., Cashy, J., Webster, K., Cella, D., General population and cancer patient norms for the functional assessment of cancer therapy-general (FACT-G) (2005) Evaluation and the Health Professions, 28 (2), pp. 192-211. , DOI 10.1177/0163278705275341pt_BR
dc.description.referenceEfficace, F., Baccarani, M., Rosti, G., Cottone, F., Castagnetti, F., Breccia, M., Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: An observational patient-centered outcome study (2012) Br J Cancer, 107 (6), pp. 904-909pt_BR
dc.description.referenceJabbour, E., Saglio, G., Hughes, T.P., Kantarjian, H., Suboptimal responses in chronic myeloid leukemia: Implications and management strategies (2012) Cancer, 118 (5), pp. 1181-1191pt_BR
dc.description.referenceEfficace, F., Breccia, M., Saussele, S., Kossak-Roth, U., Cardoni, A., Caocci, G., Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group (2012) Ann Hematol, 91 (9), pp. 1371-1381pt_BR
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
2-s2.0-84905119542.pdf170.78 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.